RPHM | Reneo Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.6800 - 18.20
52 Week Range	1.6800 - 82.90
Beta	0.14
Implied Volatility	105.88%
IV Rank	13.13%
Day's Volume	437,523
Average Volume	17,983
Shares Outstanding	3,342,880
Market Cap	60,840,416
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-04-08

Valuation
Profitability
Growth
Health
P/E Ratio	-1.08
Forward P/E Ratio	N/A
EPS	-16.80
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	RPHM

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

RPHM's peers: ADPT, RPRX, RZLT, PRME

*Chart delayed

Analyzing fundamentals for RPHM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see RPHM Fundamentals page.

Watching at RPHM technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on RPHM Technicals page.